Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
Eisen A, Somerfield MR, Accordino MK, Blanchette PS, Clemons MJ, Dhesy-Thind S, Dillmon MS, D'Oronzo S, Fletcher GG, Frank ES, Hallmeyer S, Makhoul I, Moy B, Thawer A, Wu JY, Van Poznak CH. Eisen A, et al. Among authors: dhesy thind s. J Clin Oncol. 2022 Mar 1;40(7):787-800. doi: 10.1200/JCO.21.02647. Epub 2022 Jan 18. J Clin Oncol. 2022. PMID: 35041467
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, Zalewski P, Do T, Cano P, Lam WYH, Dowden S, Grassin H, Stewart J, Moore M. Gill S, et al. J Clin Oncol. 2016 Nov 10;34(32):3914-3920. doi: 10.1200/JCO.2016.68.5776. Epub 2016 Sep 30. J Clin Oncol. 2016. PMID: 27621395 Clinical Trial.
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.
Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, Dillmon MS, Frank ES, Gandhi S, Gupta R, Mates M, Moy B, Vandenberg T, Van Poznak CH. Dhesy-Thind S, et al. J Clin Oncol. 2017 Jun 20;35(18):2062-2081. doi: 10.1200/JCO.2016.70.7257. Epub 2017 Mar 6. J Clin Oncol. 2017. PMID: 28618241 Review.
Reply to T.J. Powles et al.
Dhesy-Thind S, Fletcher GG, Clemons M, Van Poznak C; Cancer Care Ontario–American Society of Clinical Oncology Adjuvant Bone-Modifying Agents Panel. Dhesy-Thind S, et al. J Clin Oncol. 2017 Aug 10;35(23):2720-2721. doi: 10.1200/JCO.2017.73.8567. Epub 2017 Jun 27. J Clin Oncol. 2017. PMID: 28654367 No abstract available.
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.
Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B. Van Poznak C, et al. J Clin Oncol. 2017 Dec 10;35(35):3978-3986. doi: 10.1200/JCO.2017.75.4614. Epub 2017 Oct 16. J Clin Oncol. 2017. PMID: 29035643
Clinical practice guidelines in breast cancer.
Tyagi NK, Dhesy-Thind S. Tyagi NK, et al. Curr Oncol. 2018 Jun;25(Suppl 1):S151-S160. doi: 10.3747/co.25.3729. Epub 2018 Jun 13. Curr Oncol. 2018. PMID: 29910658 Free PMC article. Review.
Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer.
Awan A, Ng T, Conter H, Raskin W, Stober C, Simos D, Pond G, Dhesy-Thind S, Mates M, Kumar V, Fergusson D, Hutton B, Saunders D, Vandermeer L, Clemons M; REaCT Investigators. Awan A, et al. Among authors: dhesy thind s. J Bone Oncol. 2020 Dec 13;26:100343. doi: 10.1016/j.jbo.2020.100343. eCollection 2021 Feb. J Bone Oncol. 2020. PMID: 33425673 Free PMC article.
Systematic review on hormone receptor testing in breast cancer.
Nofech-Mozes S, Vella ET, Dhesy-Thind S, Hagerty KL, Mangu PB, Temin S, Hanna WM. Nofech-Mozes S, et al. Appl Immunohistochem Mol Morphol. 2012 May;20(3):214-63. doi: 10.1097/PAI.0b013e318234aa12. Appl Immunohistochem Mol Morphol. 2012. PMID: 22505008 Review.
51 results